Rapid communication · 27 Jan 2025
Conference abstractPublished 18 Nov 2025
Inflammatory bowel disease
HelpAge India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Inflammatory Bowel Disease (IBD), comprising Crohn’s disease and ulcerative colitis, represents a chronic, relapsing remitting inflammatory disorder of the gastrointestinal tract with significant global health impact. Its incidence has increased markedly over the past decades, particularly in developing regions undergoing rapid urbanization. While the exact etiology of IBD remains multifactorial, current evidence indicates a complex interplay among genetic susceptibility, environmental triggers, gut microbiota dysbiosis, and dysregulated mucosal immune responses. These interactions lead to chronic intestinal inflammation, epithelial barrier dysfunction, and progressive tissue damage. Clinically, IBD manifests with abdominal pain, diarrhoea, rectal bleeding, weight loss, extraintestinal complications, and impaired quality of life. Diagnosis relies on a combination of endoscopic evaluation, histopathology, biomarkers, and advanced imaging. Despite substantial advancements, early detection remains challenging due to overlapping symptoms with infectious and functional bowel disorders. Therapeutic strategies for IBD have expanded significantly, moving beyond traditional corticosteroids and immunomodulators. Biologic agents targeting TNF-α, IL-12/23 pathways, integrins, and JAK inhibitors have transformed disease management, providing improved remission rates and mucosal healing. Recent research highlights the importance of personalized medicine through biomarker-guided therapy, microbiome modulation, nutritional interventions, and emerging cell-based treatments, including mesenchymal stem cell therapy. Additionally, non-invasive monitoring using faecal calprotectin and novel imaging biomarkers is improving long-term disease assessment and relapse prediction. Despite these advances, unmet needs remain in understanding disease heterogeneity, preventing complications, and improving patient-centric outcomes. Future directions focus on precision therapeutics, early intervention strategies, and integrative approaches combining pharmacological, dietary, and lifestyle management to optimize long-term remission.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Case series · 31 Dec 2024
Infection (Covid-19) in Patients with Chronic Inflammatory Bowel Disease: A Case Series
Article · 26 Dec 2024
Outcomes of Liver Transplant in Primary Sclerosing Cholangitis with Coexisting Inflammatory Bowel Disease
Article · 23 Dec 2024
Inflammatory Bowel Diseases: Causes, Symptoms, and Advances in Treatment
Article · 29 Oct 2024
Understanding Inflammatory Bowel Disease (IBD): A Comprehensive Overview
More from this journal
The newest in Journal of Hepatology and Gastrointestinal disorders.
Conference abstract · 18 Nov 2025
Health benefits of probiotic bacteria
Conference abstract · 18 Nov 2025
Comprehensive case study of periampullary carcinoma in a 70-year-old patient: Management, nursing interventions, and recovery
Conference abstract · 18 Nov 2025
Advanced pancreatic cancer with liver metastasis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Hepatology and Gastrointestinal disorders
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Calvin Moses Kalukursa”

